Stockscreener 앱 받기
16.99
0.13%
0.65
Sanara Medtech Inc 주식(SMTI)의 최신 뉴스
Sanara MedTech Inc. (NASDAQ:SMTI) Q4 2025 Earnings Call Transcript - Insider Monkey
Retail Trends: Can Sanara MedTech Inc maintain sales growth2026 Technical Patterns & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Sanara MedTech Hits 52-Week Low of $17.54 Amidst Market Struggles - Markets Mojo
Sanara MedTech shares rise more than 3% despite fourth-quarter earnings miss - MSN
Sanara MedTech (SMTI) to Release Quarterly Earnings on Wednesday - Defense World
Sanara MedTech Inc. 2025 Business Overview: Surgical Product Focus, Innovation Strategy, and Regulatory Compliance - Minichart
Sanara MedTech Inc. (SMTI) Q4 earnings miss estimates - MSN
Sanara MedTech Inc (SMTI) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... By GuruFocus - Investing.com Canada
Sanara MedTech (NASDAQ: SMTI) ends THP unit, doubles down on surgery - Stock Titan
Sanara MedTech Inc (SMTI) Q4 2025 Earnings Call Highlights: Reco - GuruFocus
Targets Report: Can Sanara MedTech Inc deliver consistent dividends2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Sanara MedTech Reports Strong 2025 Financial Results With 19% Revenue Growth, Reaffirms 2026 Guidance - Minichart
Sanara MedTech Inc. (SMTI) Q4 and Full Year 2025 Earnings: Revenue Hits $103.1 Million With 19% Growth - Bayelsa Watch
Sanara MedTech Q4 2025 Earnings Call Transcript - MarketBeat
Sanara Medtech earnings missed by $0.52, revenue fell short of estimates - Investing.com Canada
Sanara MedTech Inc. (SMTI) Q4 Earnings: Misses on EPS, Revenue Recap - AlphaStreet
Sanara MedTech Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Sanara MedTech Q4 2025 misses EPS forecast, stock drops - Investing.com
Sanara MedTech Inc. (SMTI) Misses Q4 EPS Estimates by 215.9% - AlphaStreet
Sanara MedTech Inc. (SMTI) Q4 Earnings Miss Estimates - Yahoo Finance
Sanara Medtech Inc. Reaffirms Revenue Guidance for the Full Year Ending December 31, 2026 - marketscreener.com
Sanara MedTech stock rises over 3% despite fourth quarter miss By Investing.com - Investing.com India
Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance - The Manila Times
Sanara MedTech reports FY2025 revenue $103.1M, Q4 revenue $27.5M and Adjusted EBITDA $17.0M - TradingView
Sanara MedTech posts higher Q4 revenue, reaffirms guidance - TradingView
Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and - GlobeNewswire
Sanara MedTech Inc. (SMTI) Q4 Results Fall Short of Projections - Bitget
Sanara MedTech (SMTI) CEO receives 25,430-share restricted stock grant vesting through 2029 - Stock Titan
Sanara MedTech (SMTI) grants restricted stock to controller vesting through 2029 - Stock Titan
Sanara MedTech (SMTI) awards COO 13,956 restricted shares - Stock Titan
Sanara MedTech (SMTI) CFO awarded 12,687 restricted shares vesting 2027-2029 - Stock Titan
What To Expect From Sanara MedTech Inc (SMTI) Q4 2025 Earnings - GuruFocus
Can Sanara MedTech Inc grow without external fundingDay Trade & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Price-Driven Insight from (SMTI) for Rule-Based Strategy - Stock Traders Daily
Is Sanara MedTech Inc undervalued by DCF analysisWeekly Trend Recap & Weekly Momentum Stock Picks - baoquankhu1.vn
Sanara MedTech (NASDAQ:SMTI) Trading Up 0.8%Here's What Happened - MarketBeat
Aug Selloffs: Can Sanara MedTech Inc maintain sales growth2026 Earnings Surprises & High Accuracy Trade Alerts - baoquankhu1.vn
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds - Orthopedics This Week
Sanara MedTech (SMTI) upgraded to strong buy: Here's what you should know - MSN
Sanara MedTech study shows cost savings with CellerateRX powder By Investing.com - Investing.com India
Sanara MedTech Inc. Announces Publication of Peer-Reviewed - GlobeNewswire
Sanara MedTech study shows cost savings with CellerateRX powder - Investing.com
Sanara MedTech (SMTI) Study Highlights Cost-Effectiveness of Cel - GuruFocus
Spine surgery wounds: CellerateRX study finds $3,852 saved per patient - Stock Titan
Sanara MedTech (SMTI) CEO has shares withheld to cover tax on RSU vesting - Stock Titan
(SMTI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Sanara MedTech (SMTI) CEO corrects Form 4 to 414 tax-withheld shares - Stock Titan
Merger Talk: Can Sanara MedTech Inc navigate macro headwindsWeekly Investment Summary & Daily Momentum Trading Reports - baoquankhu1.vn
Valuation Update: Is Sanara MedTech Inc undervalued by DCF analysisRecession Risk & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 - marketscreener.com
Sanara MedTech (SMTI) CEO has 491 shares withheld to cover tax on vesting - Stock Titan
Sanara MedTech Unveils 2026 Strategy in Investor Presentation - TipRanks
Sanara MedTech (NASDAQ: SMTI) furnishes 2026 outlook deck - Stock Titan
SMTI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SMTI Should I Buy - Intellectia AI
SMTI PE Ratio & Valuation, Is SMTI Overvalued - Intellectia AI
Sanara MedTech (SMTI) COO has shares withheld to cover taxes - Stock Titan
Sanara MedTech (SMTI) CFO uses 437 shares to cover tax withholding - Stock Titan
Sanara MedTech (SMTI) Controller has 149 shares withheld for taxes - Stock Titan
(SMTI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
0.03%
0.36%
자본화:
|
볼륨(24시간):